key: cord-0809349-682q3ddv
authors: Boumaza, Asma; Gay, Laetitia; Mezouar, Soraya; Bestion, Eloïne; Diallo, Aïssatou Bailo; Michel, Moise; Desnues, Benoit; Raoult, Didier; La Scola, Bernard; Halfon, Philippe; Vitte, Joana; Olive, Daniel; Mege, Jean-Louis
title: Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis
date: 2021-01-25
journal: J Infect Dis
DOI: 10.1093/infdis/jiab044
sha: 96c071854d8cbe8e28c05064a3904dea58794cb6
doc_id: 809349
cord_uid: 682q3ddv

BACKGROUND: Covid-19 clinical expression is pleiomorphic, severity is related to age and comorbidities such as diabetes and hypertension, and pathophysiology involves aberrant immune activation and lymphopenia. We wondered if the myeloid compartment was affected during Covid-19 and if monocytes and macrophages could be infected by SARS-CoV-2. METHODS: Monocytes and monocyte-derived macrophages from Covid-19 patients and controls were infected with SARS-CoV-2, and extensively investigated with immunofluorescence, viral RNA extraction and quantification, total RNA extraction followed by reverse transcription and q-PCR using specific primers, supernatant cytokines (IL-10, TNF-α, IL-1β, IFN-β, TGF-β1 and IL-6), flow cytometry. The effect of M1- versus M2-type or no polarization prior to infection was assessed. RESULTS: SARS-CoV-2 efficiently infected monocytes and MDMs but their infection is abortive. Infection was associated with immunoregulatory cytokines secretion and the induction of a macrophagic specific transcriptional program characterized by the upregulation of M2-type molecules. In vitro polarization did not account for permissivity to SARS-CoV-2, since M1- and M2-type MDMs were similarly infected. In Covid-19 patients, monocytes exhibited lower counts affecting all subsets, decreased expression of HLA-DR, and increased expression of CD163, irrespective of severity. CONCLUSION: SARS-CoV-2 drives monocytes and macrophages to induce host immunoparalysis for the benefit of Covid-19 progression.

M a n u s c r i p t 4 

The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in Wuhan (China) at the end of 2019 and caused the coronavirus disease of 2019 (Covid-19) pandemic, with 85 million cases and 1,800,000 deaths to date (1). Covid-19 is characterized by a strikingly heterogeneous clinical presentation and prognosis. Most patients are pauci-symptomatic or have fever, cough and fatigue, while a minority experience progression to an acute respiratory distress syndrome or other critically severe conditions. The severity of the disease is related to underlying conditions such as hypertension, diabetes, coronary heart diseases or obesity (2) . The mechanisms remain elusive, but evidence for a prominent role of the immune system is accumulating. The severity of Covid-19 pneumonia is associated with lymphopenia and a cytokine release syndrome (CRS) (3) , which contributes to the massive migration of T cells into tissues, mainly the lung, and accumulation of T cells within lesions (4) .

There is evidence that myeloid cells are involved in the pathophysiology of coronavirus infection, either directly, as virus target, or indirectly, as CRS effectors (5) . Macrophages are susceptible to MERS-CoV and SARS-CoV-1 infection (6) . Macrophage and monocyte accumulation in the alveolar lumen was demonstrated in a mouse model of SARS-CoV-2 expressing human angiotensin-converting enzyme 2 (ACE2) (7) . SARS-CoV-2 nucleocapsid protein was detected in lymph nodes and spleen-associated CD169 + macrophages from Covid-19 patients (8). Finally, single cell RNA sequencing of pulmonary tissue from Covid-19 patients revealed an expansion of interstitial macrophages and monocyte-derived macrophages (MDM) but not of alveolar macrophages (9) .

However, whether monocytes and/or macrophages are targets of SARS-CoV-2 and whether monocyte diversity is altered in Covid-19 patients require specific investigation since most studies are based on this hypothesis.

Monocytes are innate hematopoietic cells that maintain vascular homeostasis and ensure early responses to pathogens during acute infections. CD14 and CD16 surface antigens: delineate A c c e p t e d M a n u s c r i p t 5 three human monocyte subsets: classical CD14 + CD16 -, intermediate CD14 + CD16 + , and non-classical CD14 -CD16 + (10,11). In murine models, classical monocytes are the precursors of non-classical monocytes (12). Monocyte subsets exhibit functional specialization. During bacterial infection, classical monocytes are recruited to the sites of inflammation, exert typical phagocytic functions and differentiate into inflammatory dendritic cells or macrophages. Non-classical monocytes crawl along vasculature and surveil the vascular tissue (13). Alterations of monocyte subset frequency were reported in infectious and inflammatory diseases(10). While macrophages largely arise from monocytes in acute situations such as infection, under homeostatic conditions most tissue macrophages are of embryonic origin and monocytes merely renew this population (14) .

Consequently, the mobilization of immune cells in Covid-19 might lead to macrophage populations of multiple origin in tissue lesions.

We show here that SARS-CoV-2 can infect human monocytes and MDMs but their infection is abortive. SARS-CoV-2 infection stimulated the production of immunoregulatory cytokines, interleukin (IL)-6 and IL-10 in both cell types and triggered in MDMs an original transcriptional program enriched with M2-type genes. MDM polarization did not account for permissivity to the virus since M1-and M2-polarized cells were similarly infected. In Covid-19 patients, the counts of classical, intermediate and non-classical monocytes were decreased, irrespective of the level of severity. CD163 expression, a molecule associated with the immunoregulatory phenotype, was significantly higher than in healthy controls, whereas that of HLA-DR was decreased. Hence, SARS-CoV-2 drives circulating monocytes and macrophages, inducing immunoparalysis of the host for the benefit of Covid-19 progression.

Seventy-six consecutive patients with confirmed SARS-CoV-2 infection (RT-PCR, Life Technologies) were included. Upon diagnosis, patients underwent standard of care laboratory tests. According to French law, the patients received information that excess samples and clinical data might be used M a n u s c r i p t 6 for research purposes, and retained the right to oppose (15, 16) . Epidemiological, demographic, clinical, laboratory and outcome data were obtained from a retrospective review of medical records (Table 1) .

Peripheral blood mononuclear cells (PBMCs) were isolated from the blood of Covid-19 patients and from buffy coats of healthy donors (Convention N°7828, "Etablissement Français du Sang", France) by density gradient centrifugation using Ficoll (Eurobio) (17) . Monocytes were purified by CD14 selection using magnetic beads (Miltenyi-Biotec) with a purity (98%) evaluated by flow cytometry and cultured in RPMI-1640 (Life Technologies) containing 10% inactivated human AB-serum, 2mM glutamine (Sigma-Aldrich), 100U/mL penicillin and 50µg/mL streptomycin (Life Technologies). After 3 days, the medium was replaced by RPMI-1640 containing 10% fetal bovine serum (FBS, Life Technologies) and 2mM glutamine, and cells were differentiated into macrophages for 4 additional days.

THP-1 cell line were cultured in RPMI-1640 containing 10% FBS, 2mM glutamine and 100U/mL penicillin and 50µg/mL streptomycin and differentiated into macrophages after treatment with 50ng/ml phorbol-12-myristate-13-acetate (Sigma-Aldrich) for 48 hours (18, 19) .

SARS-CoV-2 strain IHU-MI3 was obtained after Vero-E6 cells (American type culture collection ® CRL-1586™) infection in MEM (Life Technologies) supplemented with 4% FBS as previously described (20). In some experiment SARS-CoV-2 was heat-inactivated at 56°C during 1h (21).

Cells were infected with 50 µl virus suspension (0.25, 0.5 or 0.1 multiplicity of infection (MOI)) for 24 or 48 hours at 37°C in the presence of 5% CO 2 and 95% air in a humidified incubator.

A c c e p t e d M a n u s c r i p t Immunofluorescence After a 24 or 48-hours infection, cells were incubated in phosphate buffer saline (PBS) supplemented with 5% FBS and 0.5% Triton X-100 for 30 minutes, washed and incubated with an anti-SARS-CoV-2 spike protein (subunit 1) antibody (Life Technologies). Secondary antibody alone was used as background control. Nuclei and F-actin were stained using DAPI and Phalloidin (Life Technologies) respectively. An LSM800 Airyscan confocal microscope (Zeiss) and a 63X oil objective were used.

Viral RNA was extracted from infected cells using NucleoSpin® Viral RNA Isolation kit (Macherey-Nagel). Virus detection was performed using One-Step RT-PCR SuperScript™ III Platinum™ (Life Technologies). Thermal cycling was achieved at 55°C for 10 minutes for RT, pursued by 95°C for 3 minutes and then 45 cycles at 95°C for 15 seconds and 58°C for 30 seconds using a LightCycler480 system (Roche). The primers and the probes were designed against the E gene (20). Viral quantification was expressed as threshold cycle (Ct) values normalized with the actin housekeeping gene.

Total RNA was extracted from cells (2.10 6 cells/well) using the RNeasy Mini Kit (Qiagen) and DNase I treatment (22) and evaluated using a spectrophotometer (Nanodrop Technologies). RT-PCR was performed using a Moloney murine leukemia virus-reverse transcriptase kit (Life Technologies) and oligo(dT) primers, Smart SYBRGreen fast Master kit (Roche Diagnostics) and a CFX Touch Detection System (Bio-Rad) using specific primers ( Table 2 ). The results were normalized using the housekeeping endogenous control ACTB gene and expressed as 2 -ΔCt whith ΔCt=Ct Target -Ct Actin (23).

A c c e p t e d M a n u s c r i p t 8 Immunoassays IL-10, tumor necrosis factor (TNF)-α, IL-1β, interferon (IFN)-β, transforming growth factor (TGF)-β1 (R&D Systems) and IL-6 (Clinisciences) were quantified in cell supernatants. The sensitivity was (pg/ml) 15.4 for IL-6, 3.9 for IL-10, 5.5 for TNF-α, 0.125 for IL-1β, 50 for IFN-β and 4.61 for TGF-β1.

PBMCs from healthy donors or Covid-19 patients were resuspended in PBS containing 5% FBS and 2mM EDTA (Sigma-Aldrich) for 20 minutes before staining with fluorochrome-conjugated mouse IgG1: CD3(UCHT1), CD20(B9E9), CD14(RMO52), CD16(3G8) (Beckman Coulter); HLA-DR(G46-6) and CD163(GHI/61) (BD Biosciences), and appropriate isotype controls. A minimum of 50,000 events were acquired for each sample using a BD CantoII instrument (BD Biosciences) analyzed with FlowJo software (Tree Star).

Statistical analysis was performed with GraphPad Prism, using the two-way ANOVA test for viral quantification and transcriptional analysis, nonparametric Kruskall-Wallis test for group comparison, Mann-Whitney U test for cytokine levels, and t-test for flow cytometry results with monocyte populations and surface marker expression. Turkey's and Sidak's tests were used for post-hoc comparisons. qRT-PCR data including principal component analysis (PCA) and hierarchical clustering of gene expression, were analyzed using the ClustVis webtool(24). Significance was set at P<0.05.

SARS-CoV-2 strain IHU-MI3 was cultivated in Vero E6 cells that were efficiently infected (Ct=18.7)

after 24 hours, but a lytic process interfered with the measurement of viral replication (Supplementary figure 1) . Monocytes and macrophages express receptors for SARS-CoV-2 (25), A c c e p t e d M a n u s c r i p t 9 suggesting that the virus targets myeloid cells. We wondered whether SARS-CoV-2 was able to infect human monocytes and macrophages. Monocytes and MDM were incubated with SARS-CoV-2 strain IHU-MI3 for 24, 48 and 72-hours and infection level was measured by RT-PCR and immunofluorescence. Monocytes were infected after 24 hours (mean Ct/actin = 7.8); their viral load increased slightly at 48h (mean Ct/actin = 6.8) but it remained constant thereafter (mean Ct/actin = 7.9) (Figure 1A) . Similarly, MDMs were efficiently infected with the SARS-CoV-2 strain after 24 (mean Ct/actin = 9.5) and 48 hours (mean Ct/actin = 9.8) and the viral load gradually decreased with a Ct/actin = 11.5 (mean) at 72 hours, suggesting an abortive infection. Finally, when monocytes and MDM were incubated with heat-inactivated SARS-CoV-2, they more efficiency eliminated the virus from 48 to 72 hours ( Figure 1A) . In contrast to Vero cells (Supplementary figure 1) , monocytes and MDMs were not uniformly infected, as observed by confocal microscopy ( Figure 1A) . We next 

As SARS-CoV-2 induced an early M1/M2 followed by a late M2 program in macrophages, we (Supplementary figure 4) . Regarding pro-and anti-inflammatory cytokines, SARS-CoV-2 stimulation significantly increased the release of both cytokine groups in M1and M2-polarized MDMs after 24 and 48 hours (Figure 3A,B) . In addition, no differences were observed in the viral load of M0, M1 or M2 macrophages (Figure 3C) . We next performed the same experiment using M0, M1 or M2 THP-1-macrophages to minimize variations. The viral load of M1 polarized THP-1-macrophages was similar to that of non-polarized (M0) counterparts. In contrast, SARS-CoV-2 load was significantly decreased in M2-polarized macrophages as compared with M0 macrophages (Figure 3C) . Although a type 2 immune response was associated with lesser infection of macrophages, their polarization did not appear critical for SARS-CoV-2 infection.

We next wondered if the frequency of monocyte subsets was affected in Covid-19 patients.

Monocyte subsets were analyzed for CD14 and CD16 expression by flow cytometry in 76 Covid-19 patients and compared to those of 41 healthy blood donors. Covid-19 patients were classified in mild (n=41,5%), moderate (n=21,3%), and severe (n=14,2%, including 8 Covid-19-related deaths). This opposite expression suggests that their activation status was shifted to an immunoregulatory program. This phenotypic profile of Covid-19 monocytes was partly recapitulated by incubating control monocytes with SARS-CoV-2 (data not shown). Finally, no significant differences in monocyte HLA-DR and CD163 expression were observed among mild, moderate, and severe patients (Figure 5) .

Hence variation of monocyte HLA-DR and CD163 expression in Covid-19 patients was induced by SARS-CoV-2 infection but was not related to subsequent disease severity.

We showed that SARS-CoV-2 efficiently infects human monocytes and macrophages. This is reminiscent of previous reports about SARS-CoV-1 that infects human macrophages but does not replicate within (27) . Macrophages infected by SARS-CoV-1 were detected in lungs of SARS patients induces IL-6 production more efficiently than other cytokines (8). We reported that IL-6 release was significantly increased in macrophages stimulated by live SARS-CoV-2 compared to heat-inactivated virus. IL-6 release is consistent with previous reports on the ability of SARS-CoV-1 to stimulate IL-6 secretion in MDM (27) . We also reported an M2-like polarization of stimulated-macrophage. This finding was in accordance with previous study reporting that M2-like infiltrating macrophages were found the major source of IL-6 in a fibrosis mice model (35) .

We found that in monocytes, SARS-CoV-2 elicited a transient program, while macrophages exhibited a more diversified transcriptional program associating inflammatory and antiinflammatory genes, which shifted to an anti-inflammatory program of M2 type at 48 hours. Hence, SARS-CoV-2 affected macrophage polarization according to the kinetics of infection. Previous reports on SARS-CoV-1 infection directly affected macrophage activation. SARS-CoV-1 polarized pulmonary monkey macrophages in a M1 profile associated with decreased viral load but persistence of inflammation (36) . SARS-CoV-1 infection, alveolar murine macrophages were repolarized to limit T cell activation (37) . Moreover, SARS-CoV-1 induced non-protective M2 polarization in lung macrophages from infected mice (38) . Whether macrophage polarization affected their capacity to control SARS-CoV-2 replication was not addressed. Using polarized macrophage, we found that nonpolarized and M1 macrophages were permissive to SARS-CoV-2. This may explain why obesity and A c c e p t e d M a n u s c r i p t estrogens favor M2 polarization (40) , this may explain why women are less affected than men by Covid-19. In addition, patients with allergic asthma seem to be less susceptible to the virus (41). Our results suggest that, instead of inducing a clear polarization, SARS-CoV-2 exacerbates macrophage responses whatever the type of polarization.

We show that Covid-19 monocytopenia affects all monocyte subsets. Consensus about the variations of monocyte counts in Covid-19 is lacking, probably because of the diversity of measurement tools and cohort outcome. A single-cell RNA sequencing study reported depletion of CD16 + monocytes, including intermediate and non-classical monocytes (42) . Expansion of IL-6 producing CD14 + CD16 + monocytes was reported in Covid-19 patients hospitalized in intensive care units (ICU) as compared with patients not requiring ICU care (33) .

upregulation. HLA-DR down-modulation is in agreement with previous studies (39, 41) , including a disease-severity-associated signature in MDM with down-modulated MHC II and type I IFN genes (27, 42) . Previously unreported CD163 upregulation in Covid-19 patients suggests monocyte polarization toward M2-type. Immunohistochemical staining of SARS pneumonia demonstrated CD163 + M2 macrophages in situ (45) . M2 polarization is the consequence of the release of immunoregulatory cytokines, but also of the interaction with the virus. IL-6 antagonizes HLA-DR expression and the addition of the specific inhibitor of IL-6 pathway, tocilizumab, partly restores it in Covid-19 patients (44) . SARS-CoV-2 and IL-6 likely synergize to down-modulate the expression of HLA-DR and to disarm microbicidal competence of monocytes and macrophages. A c c e p t e d M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t Mean fluorescence intensity (MFI) of HLA-DR and CD163 expression was investigated for CD14 + , CD14 + /CD16 + and CD16 + monocyte populations from moderate, mild and severe Covid-19 patients using t-test.

SARS-CoV-2 shedding and infectivity -Authors' reply

Cytokine release syndrome in severe COVID-19

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Immunopathogenesis of coronavirus infections: implications for SARS

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes

The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing

Developmental and functional heterogeneity of monocytes

The myeloid cell compartment-cell by cell

LOI n° 2012-300 du 5 mars 2012 relative aux recherches impliquant la personne humaine

Décret n° 2016-1537 du 16 novembre 2016 relatif aux recherches impliquant la personne humaine

High concentrations of serum soluble E-cadherin in patients with Q fever

macrophages and polarizing ability of LPS and food compounds

Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection

Host-viral infection maps reveal signatures of severe COVID-19 patients

SARS-coronavirus replication in human peripheral monocytes/macrophages

Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis

SARS-CoV Regulates immune function-related gene expression in human monocytic cells

The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-mediated RIG-I ubiquitination

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycininduced lung fibrosis

Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge

Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice

Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection

Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic

Estrogen accelerates the resolution of inflammation in macrophagic cells

COVID-19, asthma, and biological therapies: What we need to know

A single-cell atlas of the peripheral immune response to severe COVID-19. Infectious Diseases (except HIV/AIDS

Complex immune dysregulation in COVID-19 patients with severe respiratory failure

Pulmonary pathology of early phase COVID-19 pneumonia in a patient with a benign lung lesion

A c c e p t e d M a n u s c r i p t